s20098 has been researched along with Depression, Involutional in 134 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 40 (29.85) | 29.6817 |
| 2010's | 83 (61.94) | 24.3611 |
| 2020's | 11 (8.21) | 2.80 |
| Authors | Studies |
|---|---|
| Du, ZW; Li, LD; Nan, S; Naveed, M; Sheng, G; Zhang, J; Zhou, QG; Zhou, YP; Zhu, MY | 1 |
| Arango, C; Buitelaar, JK; Chimits, D; Falissard, B; Fegert, JM; Marx, U; Olivier, V; Pénélaud, PF | 1 |
| Cerou, M; Chenel, M; Comets, E; Peigné, S | 1 |
| Holper, L | 1 |
| Bao, YP; Du, LT; Fan, TT; Fu, Y; Gao, XJ; Guo, LH; Hao, XN; Li, LZ; Li, SX; Lin, X; Liu, L; Liu, Z; Lu, L; Mi, WF; Shi, Y; Si, TM; Sun, HQ; Tabarak, S; Wang, L; Wang, XQ; Zhang, HY; Zhang, SZ; Zhang, WH | 1 |
| Dimitrakopoulos, S; Konstantakopoulos, G; Michalopoulou, PG | 1 |
| Buturak, ŞV; Erdoğan, Ç; Koçak, OM; Özdemir Rezaki, H | 1 |
| Benichou, J; de Bodinat, C; Desobry, X; Gorwood, P; Moore, N; Picarel-Blanchot, F; Secouard, MC; Wattez, M | 1 |
| Aguglia, E; Álvarez Martínez, E; Benichou, J; de Bodinat, C; Falkai, P; Figueira, ML; Gorwood, P; Mertens, J; Moore, N; Olivier, V; Picarel-Blanchot, F; Wattez, M | 1 |
| Abdul Karim, M; Al-Baz, N; Alabdulla, M; Haddad, PM; Ouanes, S | 1 |
| Chakravarty, R; Gupta, R; Rai, B | 1 |
| Leung, SM | 1 |
| Boyer, P; de Bodinat, C; Goodwin, GM; Heun, R; Picarel-Blanchot, F; Thomas, P | 1 |
| Brignone, M; Danchenko, N; Diamand, F; Florea, I; Jacobsen, PL; Thase, ME; Vieta, E | 1 |
| Bhatia, MS; Gupta, K; Gupta, LK; Gupta, R; Tripathi, AK | 1 |
| Deuschle, M; Fischer, EC; Zapp, AA | 1 |
| Cadour, S; Grouin, JM; Kennedy, SH; Picarel-Blanchot, F; Robert, V | 1 |
| Cribb, L; Menon, R; Ng, CH; Sarris, J | 1 |
| Dragheim, M; Nielsen, RZ; Papakostas, GI; Tonnoir, B | 1 |
| Gao, KR; Li, HF; Shen, YF; Yu, H; Yu, YM | 1 |
| Ahokas, A; Avedisova, A; de Bodinat, C; Heun, R; Kennedy, SH; Olivier, V; Picarel-Blanchot, F | 1 |
| Cheng, Z; Colin, P; Vermeulen, A; Xie, F | 1 |
| Aguado, J; Brandt, L; Cainzos-Achirica, M; Castellsagué, J; Cortés, J; Deltour, N; Falissard, B; Forns, J; Giner-Soriano, M; Hägg, D; Hallas, J; Hellfritzsch, M; Jacquot, E; Morros, R; Perez-Gutthann, S; Perlemuter, G; Pladevall-Vila, M; Poblador-Plou, B; Pottegård, A; Prados-Torres, A; Reinders, T; Reutfors, J; Schink, T; Timmer, A | 1 |
| Antonova, AA; Barylnik, YB; Filippova, NV; Shuldyakov, AA | 1 |
| Bayle, F; Corruble, E; Courtet, P; Gorwood, P; Llorca, PM; Vaiva, G | 1 |
| Corruble, E; Demyttenaere, K; Hale, A; Kasper, S; Picarel-Blanchot, F; Quera-Salva, MA | 1 |
| Amore, M; Fusar-Poli, P; Girardi, P; Innamorati, M; Pompili, M; Serafini, G; Sher, L; Venturini, P | 1 |
| Kennedy, SH; Picarel-Blanchot, F; Stein, DJ | 1 |
| De Berardis, D; Di Giannantonio, M; Fornaro, M; Marini, S; Martinotti, G; Moschetta, FS; Serroni, N; Valchera, A | 1 |
| Chatzimanolis, I; Jonsson, L; Kourlaba, G; Maniadakis, N; Mougiakos, T | 1 |
| Hajak, G; Kasper, S | 1 |
| Belaïdi, C; Corruble, E; de Bodinat, C; Goodwin, GM | 1 |
| Ahokas, A; Boyer, P; Giménez-Montesinos, N; Heun, R; Olivier, V; Pontes-Soares, F | 1 |
| Descalzi, VI; Fernández, MG; Gruz, F; Papale, RM; Raffa, S; Santucci, C; Videla, MG; Yantorno, S | 1 |
| Barbui, C; Becker, T; Cipriani, A; Guaiana, G; Koesters, M | 1 |
| Delmonte, D; Smeraldi, E | 1 |
| Bayle, F; Corruble, E; Courtet, P; Frank, E; Gorwood, P; Gressier, F; Llorca, PM; Vaiva, G | 1 |
| Assetta, M; De Berardis, D; Di Giannantonio, M; Fornaro, M; Marini, S; Martinotti, G; Moschetta, FS; Olivieri, L; Onofrj, M; Salone, A; Serroni, N; Srinivasan, V; Valchera, A | 1 |
| Carvalho, AF; Cha, DS; MacIsaac, SE; Mansur, RB; McIntyre, RS | 1 |
| de Bodinat, C; Lejoyeux, M; Matharan, S | 1 |
| Chiodo, D; Davies, SJ; Guaiana, G; Gupta, S; Haederle, K; Koesters, M | 1 |
| Pae, CU | 1 |
| Levin, YI; Poluéktov, MG | 1 |
| Avedisova, A; Belaïdi, C; de Bodinat, C; Giménez-Montesinos, N; Kennedy, SH | 1 |
| Hsu, CC; Hu, GC; Huang, KL; Lee, WY; Lu, CH; Lu, WC; Wang, YY | 1 |
| Crutel, VS; Fones Soon Leng, C; Huang, YS; Kim, YS; Shu, L; Sulaiman, AH | 1 |
| Häggström, L; Montgomery, SA; Nielsen, RZ; Poulsen, LH | 1 |
| Brignone, M; Ereshefsky, L; Francois, C; Lançon, C; Llorca, PM; Rive, B; Salah, S | 1 |
| Ivanchuk, ÉG; Rostovshchikov, VV; Tarakanova, EA | 1 |
| Brunnauer, A; Buschert, V; Distler, G; Fric, M; Laux, G; Sander, K; Segmiller, F; Zwanzger, P | 1 |
| Bleich, S; Correll, C; Eberlein, CK; Frieling, H; Kahl, KG; Pul, R; Sühs, KW | 1 |
| Bayle, F; Corruble, E; Courtet, P; Demyttenare, K; Gorwood, P; Llorca, PM; Vaiva, G | 1 |
| Domotor, E; Hermanne, EF | 1 |
| Chang, CC; Chang, HA; Huang, SY; Kao, LC; Kuo, TB; Tzeng, NS; Yeh, TC | 1 |
| Oravecz, R; Stuhec, M | 1 |
| Allaïli, N; Choucha, W; Delaveau, P; Fossati, P; Girault, N; Jabourian, M; Laredo, J; Lehericy, S; Lemogne, C | 1 |
| Avedisova, A; Belaïdi, C; de Bodinat, C; Kennedy, SH; Picarel-Blanchot, F | 1 |
| de Bodinat, C; Dehelean, P; Nuss, P; Picarel-Blanchot, F; Raba, V; Udristoiu, T | 1 |
| Aalto-Setälä, M; Brignone, M; Campbell, R; Cure, S; Danchenko, N; Diamand, F; Hallinen, T; Kolasa, K; Koponen, H; Soini, E | 1 |
| Carano, A; de Bartolomeis, A; De Berardis, D; De Lauretis, I; Di Giannantonio, M; Fornaro, M; Girinelli, G; Iasevoli, F; Martinotti, G; Matarazzo, I; Mazza, M; Orsolini, L; Perna, G; Serroni, N; Tomasetti, C; Valchera, A; Vellante, F | 1 |
| Becker, A; Braun, H; Eisenacher, S; Englisch, S; Jung, HS; Lewien, A; Meyer-Lindenberg, A; Nowak, U; Thiem, J; Zink, M | 1 |
| Corral, R; Gargoloff, PD; Gargoloff, PR; Herbst, L; Marquez, M; Martinotti, G | 1 |
| Barthel, B; Hajak, G; Laux, G; Lemke, M; Volz, HP | 1 |
| Danchenko, N; François, C; Lançon, C; Nielsen, R; Williams, V | 1 |
| Chang, CC; Chang, HA; Huang, SY; Kuo, TBJ; Tzeng, NS; Yeh, CB | 1 |
| Arranz, B; San, L | 1 |
| Cardinali, DP; Hardeland, R; Pandi-Perumal, SR; Poeggeler, B; Spence, DW; Srinivasan, V; Trakht, I | 1 |
| Goodwin, GM | 2 |
| Gorwood, P; Le Strat, Y | 1 |
| Lam, RW | 4 |
| Kennedy, SH | 2 |
| Dolder, CR; Nelson, M; Snider, M | 1 |
| Manlosa, NB; Seliverstov, MI; Sharma, S; Shiovitz, TM; Song, JL | 1 |
| Hamon, M; Kasper, S | 1 |
| Dhir, A; Kulkarni, SK | 1 |
| Brown, GM; Cardinali, DP; Moscovitch, A; Pandi-Perumal, SR; Spence, DW; Srinivasan, V | 1 |
| Emsley, R; Goodwin, GM; Rembry, S; Rouillon, F | 1 |
| Popoli, M | 1 |
| Dubovsky, SL; Warren, C | 1 |
| Tessmer, M | 1 |
| Kálmán, J; Kálmán, S | 1 |
| Mendlewicz, J | 1 |
| Owen, RT | 1 |
| Rohmer, JG | 1 |
| Kennedy, SH; Rizvi, SJ | 1 |
| Baylé, FJ; Hajak, G; Hoogendijk, WJ; Kasper, S; Montejo, AL; Picarel-Blanchot, F; Quera-Salva, MA; Rybakowski, JK; Smeraldi, E; Wirz-Justice, AM; Wulff, K | 1 |
| Baldwin, DS; Bazire, S; Haddad, PM; McAllister-Williams, RH | 1 |
| Caputo, A; Fava, M; Post, A; Shah, A; Stahl, SM; Trivedi, MH | 1 |
| Guilleminault, C; Lemoine, P; Quera-Salva, MA | 1 |
| Caputo, A; Post, A; Schatzberg, A; Shah, A; Stahl, S; Zajecka, J | 1 |
| de Bodinat, C; Guardiola-Lemaitre, B; Millan, MJ; Mocaër, E; Muñoz, C; Renard, P | 1 |
| Gorwood, P | 1 |
| Llorca, PM | 2 |
| Corral, RM; Gentil, V; Hale, A; Mencacci, C; Ruiz, JS; Severo, CA | 1 |
| Acciavatti, T; Cavuto, M; Conti, C; Conti, P; De Berardis, D; Di Giannantonio, M; Di Iorio, G; Janiri, L; Martinotti, G; Moschetta, FS; Olivieri, L; Serroni, N | 1 |
| Jakovljević, M | 1 |
| Alvarez, JC; Barbot, F; Guilleminault, C; Hartley, S; Lofaso, F; Quera Salva, MA | 1 |
| Hickie, IB; Rogers, NL | 1 |
| Guilleminault, C; Hajak, G; Keufer-Le Gall, S; Laredo, J; Montplaisir, J; Philip, P; Quera-Salva, MA | 1 |
| Howland, RH | 1 |
| Demyttenaere, K | 1 |
| Kar, N; Singh, SP; Singh, V | 1 |
| Coogan, AN; Thome, J | 1 |
| Carney, RM; Shelton, RC | 1 |
| Hatzinger, M; Imboden, C | 1 |
| Laux, G | 1 |
| De Berardis, D; Di Giannantonio, M; Di Iorio, G; Di Nicola, M; Gambi, F; Janiri, L; Martinotti, G; Onofrj, M; Sepede, G | 1 |
| Di Giannantonio, M; Martinotti, G | 1 |
| Corruble, E; Hale, A; Kasper, S; Lemoine, P; Montgomery, SA; Quera-Salva, MA | 1 |
| Boyer, P; de Bodinat, C; Emsley, R; Goodwin, GM; Rouillon, F | 1 |
| D'haenen, H; Hale, A; Lôo, H | 1 |
| Emsley, R; Kennedy, SH | 1 |
| Montgomery, SA | 1 |
| Fuchs, E; Schmelting, B; Simon, M | 1 |
| Bosker, FJ; den Boer, JA; Meesters, Y | 1 |
| Rouillon, F | 1 |
| Norman, TR | 1 |
| Dubocovich, ML | 1 |
| Guilleminault, C; Zupancic, M | 1 |
| Bánki, MC | 1 |
| Chapotot, F; Guilleminault, C; Hartley, S; Laredo, J; Lofaso, F; Moulin, C; Quera Salva, MA; Vanier, B | 1 |
| Kasper, S; Olié, JP | 1 |
| Kasper, S; Montgomery, SA | 1 |
| Guilleminault, C; Lopes, MC; Quera-Salva, MA | 1 |
| Ghosh, A; Hellewell, JS | 1 |
| Alvarez, E; Guilleminault, C; Lemoine, P | 1 |
| Fulton, K; Kennedy, SH; Rasmussen, J; Rizvi, S | 1 |
58 review(s) available for s20098 and Depression, Involutional
| Article | Year |
|---|---|
The preclinical discovery and development of agomelatine for the treatment of depression.
Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Circadian Rhythm; Depressive Disorder, Major; Drug Development; Drug Discovery; Humans | 2020 |
Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder.
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Humans; Patient Acceptance of Health Care; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Vortioxetine | 2018 |
Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis.
Topics: Acetamides; Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Treatment Outcome | 2013 |
Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review.
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Humans; Neurogenesis; Neuronal Plasticity; Receptors, Melatonin; Treatment Outcome | 2013 |
[Agomelatine: fulminant liver failure in a patient with fatty liver].
Topics: Acetamides; Aged; Antidepressive Agents; Causality; Chemical and Drug Induced Liver Injury; Contraindications; Depressive Disorder, Major; Female; Hepatic Encephalopathy; Humans; Inactivation, Metabolic; Liver; Liver Function Tests; Liver Transplantation; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease | 2014 |
Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials.
Topics: Acetamides; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Humans; Middle Aged; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome; Young Adult | 2013 |
Agomelatine in depression.
Topics: Acetamides; Animals; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Melatonin; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2013 |
The mechanism, efficacy, and tolerability profile of agomelatine.
Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Disease Models, Animal; Humans; Neurogenesis; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists | 2014 |
Agomelatine versus other antidepressive agents for major depression.
Topics: Acetamides; Adult; Antidepressive Agents; Depressive Disorder, Major; Humans; Melatonin; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2013 |
Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
Topics: Acetamides; Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Male; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Treatment Outcome | 2014 |
Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
Topics: Acetamides; Adult; Aged; Antidepressive Agents; Benzofurans; Citalopram; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Humans; Hypnotics and Sedatives; Indoles; Male; Middle Aged; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Sulfides; Thiophenes; Venlafaxine Hydrochloride; Vilazodone Hydrochloride; Vortioxetine | 2014 |
Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
Topics: Acetamides; Animals; Circadian Rhythm; Depressive Disorder, Major; Dopamine; Frontal Lobe; Humans; Hypnotics and Sedatives; Melatonin; Norepinephrine; Randomized Controlled Trials as Topic; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists | 2008 |
The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives.
Topics: Acetamides; Affect; Antidepressive Agents; Brain; Depressive Disorder, Major; Humans; Indenes; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Sleep; Sleep Initiation and Maintenance Disorders | 2009 |
Agomelatine, an innovative pharmacological response to unmet needs.
Topics: Acetamides; Animals; Antidepressive Agents; Chronic Disease; Circadian Rhythm; Depressive Disorder, Major; Humans; Models, Animal; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Treatment Outcome | 2008 |
Addressing circadian rhythm disturbances in depressed patients.
Topics: Acetamides; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Sleep; Sleep Disorders, Circadian Rhythm; Time Factors; Treatment Outcome | 2008 |
Treating each and every depressed patient.
Topics: Acetamides; Age Factors; Antidepressive Agents; Anxiety; Chronic Disease; Circadian Rhythm; Depressive Disorder, Major; Female; Humans; Male; Patient Selection; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Severity of Illness Index; Sex Factors; Sleep; Time Factors; Treatment Outcome | 2008 |
Agomelatine treatment of major depressive disorder.
Topics: Acetamides; Animals; Antidepressive Agents; Cytochrome P-450 Enzyme System; Depressive Disorder, Major; Humans; Randomized Controlled Trials as Topic; Receptors, Melatonin; Serotonin Antagonists | 2008 |
Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Circadian Rhythm; Depressive Disorder; Depressive Disorder, Major; Dopamine; Humans; Hypnotics and Sedatives; Norepinephrine; Randomized Controlled Trials as Topic; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin; Serotonin 5-HT2 Receptor Antagonists | 2009 |
Current investigational drugs for major depression.
Topics: Acetamides; Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Dopamine; Drug Delivery Systems; Drugs, Investigational; Hormone Antagonists; Humans; Molecular Structure; Neurotransmitter Uptake Inhibitors; Nitric Oxide; Phytotherapy; Receptors, Neurotransmitter; Steroids | 2009 |
Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine.
Topics: Acetamides; Animals; Brain; Chronobiology Disorders; Circadian Rhythm; Depressive Disorder, Major; Humans; Hypnotics and Sedatives; Melatonin; Sleep; Sleep Wake Disorders | 2009 |
Agomelatine: innovative pharmacological approach in depression.
Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Disease Models, Animal; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Sleep Wake Disorders | 2009 |
Clinical studies on the efficacy of agomelatine on depressive symptoms.
Topics: Acetamides; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Humans; Severity of Illness Index | 2009 |
Agomelatine: efficacy at each phase of antidepressant treatment.
Topics: Acetamides; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Psychiatric Status Rating Scales; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Sleep Wake Disorders | 2009 |
Agomelatine, a melatonin agonist with antidepressant properties.
Topics: Acetamides; Animals; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Sleep | 2009 |
[Agomelatine].
Topics: Acetamides; Adult; Antidepressive Agents; Depressive Disorder, Major; Humans; Hypnotics and Sedatives; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Sleep | 2009 |
[Depression as chronobiological illness].
Topics: Acetamides; Affect; Biological Clocks; Chronotherapy; Circadian Rhythm; Depression; Depressive Disorder, Major; Humans; Hypnotics and Sedatives; Melatonin; Mood Disorders; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Sleep; Sleep Deprivation; Sleep Wake Disorders; Suprachiasmatic Nucleus | 2009 |
Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders.
Topics: Acetamides; Adrenergic alpha-Antagonists; Anticonvulsants; Antidepressive Agents; Comorbidity; Depressive Disorder, Major; Drug Therapy, Combination; Histamine H1 Antagonists; Humans; Hypnotics and Sedatives; Secondary Prevention; Sleep Initiation and Maintenance Disorders; Sleep Stages; Sleep Wake Disorders; Sleep, REM | 2009 |
Agomelatine: a novel pharmacological approach to treating depression.
Topics: Acetamides; Animals; Antidepressive Agents; Anxiety; Depressive Disorder, Major; Drug Interactions; Humans; Melatonin; Secondary Prevention; Sleep Wake Disorders; Substance Withdrawal Syndrome | 2009 |
Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.
Topics: Acetamides; Antidepressive Agents; Anxiety Disorders; Depressive Disorder, Major; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists | 2010 |
The use of antidepressants in clinical practice: focus on agomelatine.
Topics: Acetamides; Animals; Antidepressive Agents; Contraindications; Depressive Disorder, Major; Drug Interactions; Drug Monitoring; Fluvoxamine; Humans; Liver; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Substance Withdrawal Syndrome | 2010 |
Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients.
Topics: Acetamides; Animals; Antidepressive Agents; Depressive Disorder, Major; Humans; Melatonin; Randomized Controlled Trials as Topic; Sleep Disorders, Circadian Rhythm; Sleep Wake Disorders | 2010 |
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Drug Design; Drug Discovery; Humans; Melatonin; Serotonin 5-HT2 Receptor Antagonists | 2010 |
Restoring circadian rhythms: a new way to successfully manage depression.
Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Humans; Remission Induction; Sertraline; Time Factors | 2010 |
The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission.
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Humans; Medication Adherence; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Remission Induction | 2010 |
The importance of early symptom relief in antidepressant treatment: focus on agomelatine.
Topics: Acetamides; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Humans; Sleep; Time Factors | 2010 |
Agomelatine for major depressive episodes.
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Humans; Randomized Controlled Trials as Topic; Secondary Prevention; Sexual Dysfunction, Physiological; Sleep Wake Disorders; Treatment Outcome | 2010 |
The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
Topics: Acetamides; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2 | 2011 |
Agomelatine as chronopsychopharmaceutics restoring circadian rhythms and enhancing resilience to stress: a wishfull thinking or an innovative strategy for superior management of depression?
Topics: Acetamides; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Humans; Hypnotics and Sedatives; Mind-Body Relations, Metaphysical; Resilience, Psychological; Sleep Disorders, Circadian Rhythm; Stress, Psychological; Suprachiasmatic Nucleus | 2011 |
Circadian rhythms, melatonin and depression.
Topics: Acetamides; Animals; Antidepressive Agents; Biological Clocks; Chronobiology Disorders; Depressive Disorder, Major; Humans; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists | 2011 |
Novel melatonin-based therapies: potential advances in the treatment of major depression.
Topics: Acetamides; Antidepressive Agents; Chronobiology Disorders; Circadian Rhythm; Depressive Disorder, Major; Humans; Melatonin; Sleep | 2011 |
A benefit-risk assessment of agomelatine in the treatment of major depression.
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Humans; Randomized Controlled Trials as Topic; Receptors, Melatonin; Risk Assessment; Serotonin Antagonists; Treatment Outcome | 2011 |
Agomelatine: a narrative review.
Topics: Acetamides; Antidepressive Agents; Antidepressive Agents, Second-Generation; Comparative Effectiveness Research; Depressive Disorder, Major; Humans; Placebos; Randomized Controlled Trials as Topic; Recurrence | 2011 |
Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal.
Topics: Acetamides; Animals; Antidepressive Agents; Depressive Disorder, Major; Humans; Randomized Controlled Trials as Topic | 2012 |
Chronotherapeutics and psychiatry: setting the clock to relieve the symptoms.
Topics: Acetamides; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Brain; Chronobiology Disorders; Chronotherapy; Circadian Rhythm; Depressive Disorder; Depressive Disorder, Major; Humans; Mental Disorders; Seasonal Affective Disorder | 2011 |
Agomelatine for the treatment of major depressive disorder.
Topics: Acetamides; Animals; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Double-Blind Method; Drug Evaluation, Preclinical; Humans; Placebos | 2011 |
Anhedonia and major depression: the role of agomelatine.
Topics: Acetamides; Anhedonia; Antidepressive Agents; Depressive Disorder, Major; Humans | 2012 |
Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control.
Topics: Acetamides; Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome | 2013 |
[Early effects of antidepressants].
Topics: Acetamides; Affect; Antidepressive Agents; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Humans; Hypnotics and Sedatives; Melatonin; Surveys and Questionnaires; Treatment Outcome | 2012 |
Why do we need new and better antidepressants?
Topics: Acetamides; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Drug Design; Drugs, Investigational; Health Services Needs and Demand; Humans; Receptors, Melatonin; Receptors, Neurotransmitter; Treatment Outcome | 2006 |
Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system.
Topics: Acetamides; Animals; Antidepressive Agents; Biological Clocks; Brain; Depressive Disorder, Major; Disease Models, Animal; Drug Evaluation, Preclinical; Drugs, Investigational; Humans; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Tupaiidae | 2006 |
Sleep disturbances and depression: a challenge for antidepressants.
Topics: Acetamides; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Drugs, Investigational; Electroencephalography; Humans; Sleep Wake Disorders; Treatment Outcome | 2006 |
Prospects for the treatment of depression.
Topics: Acetamides; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Hypnotics and Sedatives; Nerve Growth Factors; Selective Serotonin Reuptake Inhibitors; Substance P; Thiophenes; Vasopressins | 2006 |
Agomelatine targets a range of major depressive disorder symptoms.
Topics: Acetamides; Animals; Antidepressive Agents; Anxiety; Circadian Rhythm; Clinical Trials as Topic; Contraindications; Depressive Disorder, Major; Drug Evaluation, Preclinical; Humans; Receptors, Melatonin; Receptors, Serotonin; Sleep; Sleep Initiation and Maintenance Disorders; Structure-Activity Relationship | 2006 |
Agomelatine: a preliminary review of a new antidepressant.
Topics: Acetamides; Animals; Antidepressive Agents; Depressive Disorder, Major; Humans; Hypnotics and Sedatives; Receptors, Melatonin; Serotonin 5-HT2 Receptor Antagonists | 2006 |
[Agomelatine: the first "melatoninergic" antidepressant].
Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Disease Models, Animal; Humans; Hypnotics and Sedatives; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Sleep | 2006 |
Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine.
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Humans; Personality Inventory; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder.
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Humans; Hypnotics and Sedatives; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists | 2007 |
A review of the efficacy and tolerability of agomelatine in the treatment of major depression.
Topics: Acetamides; Animals; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Melatonin | 2007 |
39 trial(s) available for s20098 and Depression, Involutional
| Article | Year |
|---|---|
Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries.
Topics: Acetamides; Adolescent; Child; Counseling; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Serotonin Receptor Agonists | 2022 |
Application of Item Response Theory to Model Disease Progression and Agomelatine Effect in Patients with Major Depressive Disorder.
Topics: Acetamides; Depressive Disorder, Major; Disease Progression; Humans; Hypnotics and Sedatives; Models, Theoretical; Patient Dropouts; Treatment Outcome | 2019 |
Antidepressant effect in older depressed patients: the lessons of two agomelatine trials.
Topics: Acetamides; Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Internationality; Male; Middle Aged; Treatment Outcome | 2017 |
Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder.
Topics: Acetamides; Adult; Age Factors; Anti-Anxiety Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Substitution; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Sulfides; Time Factors; Vortioxetine | 2017 |
Effect of Agomelatine and Fluoxetine on HAM-D Score, Serum Brain-Derived Neurotrophic Factor, and Tumor Necrosis Factor-α Level in Patients With Major Depressive Disorder With Severe Depression.
Topics: Acetamides; Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Female; Fluoxetine; Humans; Hypnotics and Sedatives; Male; Middle Aged; Psychiatric Status Rating Scales; Tumor Necrosis Factor-alpha | 2017 |
Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response.
Topics: Acetamides; Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Drug Substitution; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Outcome Assessment, Health Care; Receptors, Melatonin; Selective Serotonin Reuptake Inhibitors; Serotonin Agents; Serotonin and Noradrenaline Reuptake Inhibitors; Vortioxetine; Young Adult | 2018 |
Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.
Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents; Asian People; China; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Young Adult | 2018 |
Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression.
Topics: Acetamides; Adult; Antidepressive Agents; Anxiety; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Melatonin; Middle Aged; Treatment Outcome | 2013 |
The efficacy of agomelatine in previously-treated depressed patients.
Topics: Acetamides; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Monitoring; Drug Resistance; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Psychiatric Status Rating Scales; Receptors, Melatonin; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Sertraline | 2013 |
Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial.
Topics: Acetamides; Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Double-Blind Method; Emotions; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Patient Satisfaction; Selective Serotonin Reuptake Inhibitors; Sleep; Surveys and Questionnaires; Time Factors; Treatment Outcome; Wakefulness | 2013 |
The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study.
Topics: Acetamides; Age Factors; Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Placebos | 2013 |
How to switch to agomelatine after an unsuccessful try with paroxetine or venlafaxine.
Topics: Acetamides; Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Drug Substitution; Female; Humans; Male; Middle Aged; Paroxetine; Venlafaxine Hydrochloride | 2015 |
[The results of the Russian multicenter open observational non-comparative study on the efficacy and safety of valdoxan (agomelatin) in the treatment of patients with major depressive disorder and insomnia (the VIVALDI study)].
Topics: Acetamides; Adult; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Polysomnography; Sleep Initiation and Maintenance Disorders; Sleep, REM | 2013 |
A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder.
Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Female; Humans; Male; Middle Aged; Patient Dropouts; Psychiatric Status Rating Scales; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Severity of Illness Index; Young Adult | 2014 |
Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.
Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Treatment Outcome; Young Adult | 2014 |
A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelat
Topics: Acetamides; Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sulfides; Treatment Outcome; Vortioxetine; Young Adult | 2014 |
Driving performance and psychomotor function in depressed patients treated with agomelatine or venlafaxine.
Topics: Acetamides; Adult; Automobile Driving; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychomotor Performance; Venlafaxine Hydrochloride; Visual Perception | 2015 |
Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA).
Topics: Acetamides; Adult; Aged; Antidepressive Agents; Blood Pressure; Cardiovascular Agents; Case-Control Studies; Depressive Disorder, Major; Female; Heart Rate; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Regression Analysis; Rest; Severity of Illness Index; Taiwan; Young Adult | 2016 |
Antidepressant short-term and long-term brain effects during self-referential processing in major depression.
Topics: Acetamides; Adult; Antidepressive Agents; Brain; Brain Mapping; Depressive Disorder, Major; Double-Blind Method; Emotions; Female; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Middle Aged; Prefrontal Cortex; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome | 2016 |
Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months.
Topics: Acetamides; Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; International Cooperation; Male; Middle Aged; Psychiatric Status Rating Scales; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2016 |
Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
Topics: Acetamides; Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Outpatients; Psychiatric Status Rating Scales; Romania; Severity of Illness Index; Treatment Outcome | 2016 |
Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study.
Topics: Acetamides; Adult; Antidepressive Agents; Antipsychotic Agents; Comorbidity; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Prospective Studies; Schizophrenia | 2016 |
Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study.
Topics: Acetamides; Adult; Aged; Ambulatory Care; Anhedonia; Anxiety; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Outpatients; Psychiatric Status Rating Scales; Remission Induction; Severity of Illness Index; Treatment Outcome | 2016 |
The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine.
Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Health Status; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Sulfides; Vortioxetine; Young Adult | 2017 |
Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
Topics: Acetamides; Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypnotics and Sedatives; Kaplan-Meier Estimate; Male; Melatonin; Middle Aged; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Secondary Prevention; Serotonin 5-HT2 Receptor Antagonists; Substance Withdrawal Syndrome; Treatment Outcome | 2009 |
Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
Topics: Acetamides; Actigraphy; Adolescent; Adult; Antidepressive Agents; Anxiety; Circadian Rhythm; Depression; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Middle Aged; Motor Activity; Psychiatric Status Rating Scales; Rest; Sertraline; Severity of Illness Index; Sleep; Treatment Outcome | 2010 |
Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
Topics: Acetamides; Adult; Antidepressive Agents; Anxiety; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Psychiatric Status Rating Scales; Quality of Life; Sleep; Surveys and Questionnaires; Treatment Outcome | 2010 |
Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Acetamides; Adolescent; Adult; Aged; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Quality of Life; Rhabdomyolysis; Treatment Outcome; Young Adult | 2010 |
Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Fluoxetine; Humans; Internationality; Male; Middle Aged; Patient Dropouts; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Severity of Illness Index; Young Adult | 2010 |
Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients.
Topics: Acetamides; Adult; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Melatonin; Middle Aged; Polysomnography; Selective Serotonin Reuptake Inhibitors; Sleep Stages; Treatment Outcome; Wakefulness | 2011 |
The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI.
Topics: Acetamides; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Alanine Transaminase; Antidepressive Agents; Aspartate Aminotransferases; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Private Practice; Psychiatric Status Rating Scales; Sleep Disorders, Circadian Rhythm | 2012 |
Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study.
Topics: Acetamides; Adolescent; Adult; Anhedonia; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Patient Dropouts; Pilot Projects; Psychiatric Status Rating Scales; Venlafaxine Hydrochloride | 2012 |
Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine.
Topics: Acetamides; Adult; Antidepressive Agents; Australia; Depressive Disorder, Major; Double-Blind Method; Europe; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Proportional Hazards Models; Psychiatric Status Rating Scales; Secondary Prevention; Severity of Illness Index; South Africa; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2013 |
Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.
Topics: Acetamides; Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Melatonin; Paroxetine; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Serotonin Antagonists; Treatment Outcome | 2002 |
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.
Topics: Acetamides; Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Psychiatric Status Rating Scales; Recurrence; Treatment Outcome | 2006 |
Major depressive disorder, sleep EEG and agomelatine: an open-label study.
Topics: Acetamides; Adult; Depressive Disorder, Major; Electroencephalography; Female; Follow-Up Studies; Fourier Analysis; Humans; Hypnotics and Sedatives; Male; Middle Aged; Polysomnography; Reaction Time; Sleep; Time Factors | 2007 |
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
Topics: Acetamides; Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Prospective Studies; Receptors, Melatonin; Serotonin 5-HT2 Receptor Antagonists; Severity of Illness Index; Time Factors; Treatment Outcome | 2007 |
Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
Topics: Acetamides; Adolescent; Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Prevalence; Sleep; Sleep Wake Disorders; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2007 |
A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.
Topics: Acetamides; Adult; Antidepressive Agents, Second-Generation; Arousal; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Libido; Male; Middle Aged; Orgasm; Personality Inventory; Sexual Behavior; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
37 other study(ies) available for s20098 and Depression, Involutional
| Article | Year |
|---|---|
Agomelatine: An Astounding Sui-generis Antidepressant?
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Humans; Melatonin; Naphthalenes; Receptors, Melatonin | 2022 |
Combining threshold analysis and GRADE to assess sensitivity to bias in antidepressant treatment recommendations adjusted for depression severity.
Topics: Acetamides; Adult; Amitriptyline; Antidepressive Agents; Bayes Theorem; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Network Meta-Analysis; Paroxetine; Publication Bias; Reproducibility of Results; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2020 |
Effects of agomelatine and mirtazapine on sleep disturbances in major depressive disorder: evidence from polysomnographic and resting-state functional connectivity analyses.
Topics: Acetamides; Depressive Disorder, Major; Double-Blind Method; Humans; Mirtazapine; Sleep; Treatment Outcome | 2020 |
Comparison of the Effects of Antidepressants with Different Mechanisms of Action on Efficacy, Cognitive Functions and Side Effects.
Topics: Acetamides; Adult; Antidepressive Agents; Cognition; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sleep; Surveys and Questionnaires; Young Adult | 2020 |
Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France.
Topics: Acetamides; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Female; France; Humans; Male; Middle Aged; Outpatients; Psychiatric Status Rating Scales; Quality of Life; Treatment Outcome | 2020 |
The safety of agomelatine in standard medical practice in depressed patients: A 26-week international multicentre cohort study.
Topics: Acetamides; Antidepressive Agents; Cohort Studies; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Prospective Studies; Suicide; Treatment Outcome | 2021 |
Suspected Agomelatine-induced restless legs syndrome: a case report.
Topics: Acetamides; Adult; Citalopram; Depressive Disorder, Major; Humans; Male; Restless Legs Syndrome | 2021 |
Major Depressive Disorder With Seasonal Pattern or Seasonal Affective Disorder: Diagnostic Issues With Good Response to Agomelatine.
Topics: Acetamides; Depressive Disorder, Major; Humans; Seasonal Affective Disorder; Seasons | 2021 |
Drug use evaluation: A two-year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder.
Topics: Acetamides; Depressive Disorder, Major; Humans; Mirtazapine; Pharmaceutical Preparations; Retrospective Studies; Selective Serotonin Reuptake Inhibitors | 2021 |
The effect of agomelatine and melatonin on sleep-related eating: a case report.
Topics: Acetamides; Central Nervous System Depressants; Depressive Disorder, Major; Female; Humans; Melatonin; Middle Aged; Night Eating Syndrome; Panic Disorder; Patient Compliance; Sleep Wake Disorders; Treatment Outcome; Weight Gain | 2017 |
A Case of Acute Problem Gambling Associated With Agomelatine.
Topics: Acetamides; Adult; Antidepressive Agents; Depressive Disorder, Major; Gambling; Humans; Male | 2018 |
Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder.
Topics: Acetamides; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Social Behavior; Treatment Outcome | 2018 |
A semiphysiological population pharmacokinetic model of agomelatine and its metabolites in Chinese healthy volunteers.
Topics: Acetamides; Administration, Oral; Antidepressive Agents; Area Under Curve; Asian People; Biological Variation, Population; Cross-Over Studies; Depressive Disorder, Major; Female; Healthy Volunteers; Humans; Liver; Liver Function Tests; Male; Metabolic Clearance Rate; Models, Biological; Tablets; Therapeutic Equivalency; Young Adult | 2019 |
Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case-Control Study Using Automated Health Data Sources.
Topics: Acetamides; Adolescent; Antidepressive Agents; Case-Control Studies; Chemical and Drug Induced Liver Injury; Depression; Depressive Disorder, Major; Europe; Female; Humans; Information Storage and Retrieval; Liver; Longitudinal Studies; Male; Retrospective Studies; Selective Serotonin Reuptake Inhibitors | 2019 |
[Agomelatine in the treatment of major depressive disorder: assessment of the efficacy and tolerability].
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Humans; Selective Serotonin Reuptake Inhibitors | 2019 |
A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Depressive Disorder, Major; Female; Fluoxetine; Humans; Hypnotics and Sedatives; Male; Middle Aged; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Sertraline; Treatment Outcome; Young Adult | 2013 |
Agomelatine reversal of escitalopram-induced apathy: a case report.
Topics: Acetamides; Aged; Apathy; Citalopram; Depressive Disorder, Major; Humans; Hypnotics and Sedatives; Male; Motivation; Neuropsychological Tests; Selective Serotonin Reuptake Inhibitors | 2013 |
Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.
Topics: Acetamides; Adult; Antidepressive Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Depressive Disorder, Major; Drug Administration Schedule; Drug Costs; Drugs, Generic; Greece; Humans; Markov Chains; Middle Aged; Quality-Adjusted Life Years | 2013 |
Morningness-eveningness and treatment response in major depressive disorder.
Topics: Acetamides; Activity Cycles; Adult; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Female; France; Humans; Male; Middle Aged; Prospective Studies; Social Behavior; Time Factors; Treatment Outcome | 2014 |
Agomelatine treatment of major depressive disorder in Parkinson's disease: a case series.
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Parkinson Disease | 2013 |
Agomelatine: a new option for treatment of depression?
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Humans; Meta-Analysis as Topic; Randomized Controlled Trials as Topic | 2014 |
[Problems of depressive insomnia].
Topics: Acetamides; Adult; Circadian Rhythm; Depressive Disorder, Major; Female; Humans; Hypnotics and Sedatives; Male; Melatonin; Middle Aged; Psychiatric Status Rating Scales; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2014 |
Combination of agomelatine and bupropion for treatment-resistant depression: results from a chart review study including a matched control group.
Topics: Acetamides; Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2015 |
An increase in joy after two weeks is more specific of later antidepressant response than a decrease in sadness.
Topics: Acetamides; Depressive Disorder, Major; Emotions; Female; Follow-Up Studies; Humans; Hypnotics and Sedatives; Male; Middle Aged; Outpatients; Principal Component Analysis; Sensitivity and Specificity; Surveys and Questionnaires; Treatment Outcome | 2015 |
[The temporal accuracy of agomelatine administration and comparison of antidepressant effect of agomelatine and escitalopram in major depression: a retrospective investigation at a psychiatric outpatient clinic].
Topics: Acetamides; Adult; Aged; Ambulatory Care; Ambulatory Care Facilities; Antidepressive Agents; Chronobiology Phenomena; Citalopram; Depressive Disorder, Major; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2015 |
Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case.
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Middle Aged; Moclobemide | 2016 |
Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland.
Topics: Acetamides; Antidepressive Agents; Bupropion; Cost-Benefit Analysis; Decision Trees; Depressive Disorder, Major; Finland; Humans; Markov Chains; Models, Theoretical; Piperazines; Recurrence; Sertraline; Sulfides; Treatment Outcome; Venlafaxine Hydrochloride; Vortioxetine | 2017 |
Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice.
Topics: Acetamides; Adult; Ambulatory Care; Anhedonia; Antidepressive Agents; C-Reactive Protein; Depression; Depressive Disorder, Major; Female; Humans; Hypnotics and Sedatives; Linear Models; Male; Multivariate Analysis; Treatment Outcome; Young Adult | 2017 |
Pooled Analysis of Four Non-Interventional Studies: Effectiveness and Tolerability of the Antidepressant Agomelatine in Daily Practice.
Topics: Acetamides; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Drug Therapy, Combination; Female; Germany; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Severity of Illness Index | 2017 |
Effects of depression and melatonergic antidepressant treatment alone and in combination with sedative-hypnotics on heart rate variability: Implications for cardiovascular risk.
Topics: Acetamides; Adult; Antidepressive Agents; Autonomic Nervous System; Depressive Disorder, Major; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypnotics and Sedatives; Male; Middle Aged; Outcome Assessment, Health Care; Young Adult | 2018 |
Major depression is sometimes described as the common cold of psychiatry.
Topics: Acetamides; Animals; Antidepressive Agents; Chronic Disease; Circadian Rhythm; Depressive Disorder, Major; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Treatment Outcome | 2008 |
Extreme creatine phosphokinase elevation in a 20-year-old man participating in a clinical trial of major depressive disorder.
Topics: Acetamides; Adult; Creatine Kinase; Depressive Disorder, Major; Diagnostic Errors; Dietary Supplements; Drug Monitoring; Exercise; Humans; Hypnotics and Sedatives; Male; Neuroleptic Malignant Syndrome; Randomized Controlled Trials as Topic | 2008 |
[Further evidence of the efficacy of the antidepressant Valdoxan (agomelatine) compared with conventional antidepressive drugs (from the ECNP held in Istanbul, 15 September 2009)].
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Fluoxetine; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2009 |
Agomelatine-induced akathisia with concomitant duloxetine medication: a case report.
Topics: Acetamides; Adult; Akathisia, Drug-Induced; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Hypnotics and Sedatives; Thiophenes | 2012 |
Clinical efficacy of agomelatine in depression: the evidence.
Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drugs, Investigational; Humans; Middle Aged; Multicenter Studies as Topic; Paroxetine; Treatment Outcome | 2006 |
Efficacy and tolerance profile of agomelatine and practical use in depressed patients.
Topics: Acetamides; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drugs, Investigational; Humans; Treatment Outcome | 2006 |
Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine).
Topics: Acetamides; Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Longitudinal Studies; Male; Middle Aged; Nocturnal Paroxysmal Dystonia; Periodicity; Sleep; Sleep Arousal Disorders; Sleep Stages | 2007 |